Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Aytu Biopharma (AYTU) over the last 17 years, with Q2 2025 value amounting to $6.3 million.

  • Aytu Biopharma's Shares Outstanding (Weighted Average) rose 1339.46% to $6.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $6.3 million, marking a year-over-year increase of 1339.46%. This contributed to the annual value of $6.3 million for FY2025, which is 1339.46% up from last year.
  • As of Q2 2025, Aytu Biopharma's Shares Outstanding (Weighted Average) stood at $6.3 million, which was up 1339.46% from $5.5 million recorded in Q2 2024.
  • Aytu Biopharma's Shares Outstanding (Weighted Average)'s 5-year high stood at $18.1 million during Q1 2021, with a 5-year trough of $1.3 million in Q3 2021.
  • For the 5-year period, Aytu Biopharma's Shares Outstanding (Weighted Average) averaged around $5.4 million, with its median value being $3.7 million (2023).
  • As far as peak fluctuations go, Aytu Biopharma's Shares Outstanding (Weighted Average) soared by 41289.33% in 2021, and later plummeted by 9179.5% in 2022.
  • Quarter analysis of 5 years shows Aytu Biopharma's Shares Outstanding (Weighted Average) stood at $1.3 million in 2021, then soared by 135.52% to $3.1 million in 2022, then surged by 77.4% to $5.5 million in 2023, then increased by 0.37% to $5.5 million in 2024, then grew by 13.39% to $6.3 million in 2025.
  • Its last three reported values are $6.3 million in Q2 2025, $5.5 million for Q2 2024, and $5.5 million during Q1 2024.